HI
REGN icon

Horizon Investments’s Regeneron Pharmaceuticals REGN Stock Holding History

Horizon Investments’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.83M Buy
10,129
+6,237
+160% +$4.77M 0.09% 204
2025
Q4 		$3M Sell
3,892
-15,137
-80% -$10.3M 0.04% 366
2025
Q3 		$10.7M Buy
19,029
+5,787
+44% +$3.27M 0.14% 122
2025
Q2 		$6.95M Buy
13,242
+11,608
+710% +$6.48M 0.11% 149
2025
Q1 		$1.04M Buy
1,634
+59
+4% +$40.6K 0.03% 271
2024
Q4 		$1.12M Buy
1,575
+23
+1% +$19.3K 0.03% 256
2024
Q3 		$1.63M Sell
1,552
-99
-6% -$110K 0.04% 208
2024
Q2 		$1.74M Buy
1,651
+7
+0.4% +$6.79K 0.05% 184
2024
Q1 		$1.58M Buy
1,644
+36
+2% +$34.2K 0.04% 198
2023
Q4 		$1.41M Buy
1,608
+800
+99% +$659K 0.04% 190
2023
Q3 		$665K Buy
808
+23
+3% +$18.1K 0.02% 232
2023
Q2 		$564K Sell
785
-54
-6% -$41.6K 0.02% 267
2023
Q1 		$689K Sell
839
-577
-41% -$435K 0.02% 230
2022
Q4 		$1.02M Sell
1,416
-1,634
-54% -$1.21M 0.03% 218
2022
Q3 		$2.1M Buy
3,050
+897
+42% +$565K 0.06% 109
2022
Q2 		$1.27M Sell
2,153
-2,255
-51% -$1.47M 0.04% 158
2022
Q1 		$3.08M Buy
4,408
+793
+22% +$502K 0.09% 109
2021
Q4 		$2.28M Buy
3,615
+1,283
+55% +$789K 0.07% 133
2021
Q3 		$1.41M Buy
2,332
+620
+36% +$385K 0.04% 181
2021
Q2 		$956K Sell
1,712
-570
-25% -$289K 0.03% 220
2021
Q1 		$1.08M Buy
+2,282
New +$1.11M 0.04% 196
2020
Q4 		– Sell
-2,613
Closed -$1.46M – 330
2020
Q3 		$1.46M Sell
2,613
-2,735
-51% -$1.66M 0.05% 153
2020
Q2 		$3.33M Buy
5,348
+4,290
+405% +$2.44M 0.08% 112
2020
Q1 		$517K Buy
1,058
+114
+12% +$47K 0.03% 181
2019
Q4 		$354K Buy
+944
New +$318K 0.02% 363
2019
Q3 		– Sell
-705
Closed -$221K – 525
2019
Q2 		$221K Buy
705
+203
+40% +$67.6K 0.01% 519
2019
Q1 		$206K Buy
+502
New +$207K 0.01% 409

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Horizon Investments's REGN Position: Q1 2026 in Review

Horizon Investments increased its Regeneron Pharmaceuticals (REGN) stake by 160% in Q1 2026, buying an estimated $4.77M and bringing the position to 10,129 shares worth $7.83M. The position accounts for 0.09% of the portfolio, ranked #204.

Horizon Investments first reported a position in REGN in Q1 2019 and has held it in 27 quarters since. The position peaked at $10.7M in Q3 2025. 1,396 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Horizon Investments held 10,129 shares of Regeneron Pharmaceuticals worth $7.83M as of Q1 2026.
  • Horizon Investments bought 6,237 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $4.77M.
  • Regeneron Pharmaceuticals made up 0.09% of Horizon Investments's portfolio in Q1 2026, its #204 holding.
  • Horizon Investments first reported a position in Regeneron Pharmaceuticals in Q1 2019 and has held it in 27 quarters since.
  • Horizon Investments's Regeneron Pharmaceuticals position peaked at $10.7M in Q3 2025.
  • 1,396 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Horizon Investments's 13F filing for Q1 2026, filed 15 May 2026.